Clinical trials
Rectal Neoplasms trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
71 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 3 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 4 |
| 2010 | 7 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 34 |
| Unknown status | 21 |
| Active, not recruiting | 8 |
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Terminated | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seoul National University Hospital | 12 |
| National Cancer Center, Korea | 11 |
| Asan Medical Center | 6 |
| Samsung Medical Center | 5 |
| Yonsei University | 5 |
| GlaxoSmithKline | 3 |
| Kyungpook National University Hospital | 3 |
| AbbVie (prior sponsor, Abbott) | 1 |
| Amgen | 1 |
| Chungnam National University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Rectal Neoplasms | 71 |
| Colonic Neoplasms | 20 |
| Colorectal Neoplasms | 16 |
| Neoplasm Metastasis | 5 |
| Neoplasms | 4 |
| Endometrial Neoplasms | 3 |
| Intestinal Neoplasms | 3 |
| Sigmoid Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Esophageal Neoplasms | 2 |
Trials
Showing 26 to 50 of 71. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.